May 13, 2024

COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis

Key Points

Key points are not available for this paper at this time.

Abstract

The FDA has issued an Emergency Use Authorization (EUA) for the long-acting investigational IV monoclonal antibody pemivibart (Pemgarda – Invivyd) for pre-exposure prophylaxis of COVID-19 in persons ≥12 years old (weight ≥40 kg) who have moderate to severe immune compromise and are unlikely to respond adequately to COVID-19 vaccination.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

A Mon, study studied this question.

synapsesocial.com/papers/68e6a4f8b6db643587628324 https://doi.org/https://doi.org/10.58347/tml.2024.1702e

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-192024 · 7 citations
2660. Early Experience with Use of Pemivibart for the Pre-exposure Prophylaxis of Coronavirus Disease 20192026
3Real-world outcomes following pemivibart for COVID-19 pre-exposure prophylaxis in immunocompromised patients with hematologic malignancies2025
4Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineages2024 · 11 citations
5Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised Remains2026

Ask AI

Helpful

Bookmark

View Full Paper